Med-Tech Innovation August 7, 2024
Oliver Johnson

Partnership Expands Reach of C2N’s Precivity Blood Tests in Over 75 Countries to Transform Alzheimer’s Disease Early Diagnosis and Research.

Unilabs, a leading international provider of diagnostic services, and C2N Diagnostics, LLC, a specialist in advanced diagnostic solutions in the field of Alzheimer’s disease and related neurological disorders, have announced what the companies say is a major milestone in brain health diagnostics and research across Europe and beyond.

Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N’s Precivity portfolio of blood tests on an exclusive basis in Europe, including Norway, Switzerland, and the United Kingdom. The agreement will also provide access in Peru, Saudi Arabia, and the United Arab Emirates.

“Alzheimer’s disease is...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Medical Devices, Partnerships, Trends
UN warns of military brain control
Only 20% of AI devices for children used pediatric data to train: 3 notes
Medtech firms have cut thousands of jobs this year. Will layoffs continue in 2025?
Proton therapy market in the US projected to reach $2.67 billion by 2033
How Trump’s second term will affect the medtech industry

Share This Article